EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres

Isaac Armendáriz-Castillo, Andrés Herrera-Yela, Jhommara Bautista, Andrés López-Cortés

Cancers · 20.11.2026 · 18 (22) · 3713

DOI: 10.3390/cancers18223713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.11.2026. Verfasst von Isaac Armendáriz-Castillo und 3 weiteren Autor:innen. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Between 10 and 15% of cancers maintain their telomeres without telomerase, through a recombination-based route known as alternative lengthening of telomeres (ALT). It is most common in sarcomas and gliomas. The mechanism itself is increasingly well understood, but the view from population-scale data is not: which components are perturbed most consistently across tumors, how they organize into networks, what they cost the cell metabolically, whether their expression says anything about outcome, and which existing drugs might exploit them. Here we bring together four in silico studies that used public pan-cancer data to work from gene-level alteration through networks and metabolism to clinical outcome and pharmacology, and we read them as one argument. The program is set out as five computational steps, with a sixth, experimental step that remains open. Alteration analyses of 411 telomere maintenance genes and 71 genes of ALT-associated promyelocytic leukemia (PML) bodies prioritized 20 and 13 candidates, 28 of them unique. Networks and enrichment linked those candidates to homologous recombination, break-induced replication, SUMOylation, and the DNA damage response; protein–metabolite analyses generated the untested hypothesis that nucleotide, NAD+, and methionine metabolism are engaged. A 28-gene transcriptomic score was associated with survival in sarcoma and, more weakly, in lower-grade glioma, although its discrimination was modest and, at five years in glioma, indistinguishable from chance. The five analytical steps share gene inputs and curated resources and are therefore not independent of one another. We test each step against the experimental literature and grade the evidence gene by gene. That appraisal is not uniformly favorable: TCGA carries no direct ALT status, the steps are not fully independent, the signature has never been validated externally, and the leading drug hypothesis, ATR inhibition, is contested.

Zitieren

APA

Armendáriz-Castillo, I., Herrera-Yela, A., Bautista, J., & López-Cortés, A. (2026). From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres. Cancers, 18(22), 3713. https://doi.org/10.3390/cancers18223713

Vancouver

Armendáriz-Castillo I, Herrera-Yela A, Bautista J, López-Cortés A. From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres. Cancers. 2026;18(22):3713. doi:10.3390/cancers18223713

BibTeX
@article{ArmendrizCastillo2026,
  author = {Armendáriz-Castillo, Isaac and Herrera-Yela, Andrés and Bautista, Jhommara and López-Cortés, Andrés},
  title = {From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3713},
  doi = {10.3390/cancers18223713}
}
Kostenlos starten →